COMP <GO>
CAH vs LLY // FORWARD P/E MULTIPLE
Cardinal Health Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CAH 5
— LLY 10
▲ FORWARD P/E MULTIPLE LEADER: LLY
LAST: $250.48 (-0.24%) • MKT CAP: $58.14B
forward-pe
34.6x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.70% | 83.64% | -79.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.70% | 32.36% | -2.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | 36.4x | -11.92 | CAH | /valuation <GO> |
| Free Cash Flow Yield | 3.18% | 2.30% | +0.88 | CAH | /fcf-yield <GO> |
| Operating Margin | 1.00% | 40.21% | -39.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 0.70% | 31.90% | -31.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -1.90% | 45.51% | -47.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.85% | 0.49% | +0.36 | CAH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 9.29 | -4.13 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.77% | -0.17 | CAH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 77.9 | -19.43 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 0.51 | +0.39 | CAH | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 34.6x | 26.3x | +8.35 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $58.14B | $1.33T | -$1.28T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAH REV | LLY REV | CAH GROSS % | LLY GROSS % | CAH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $222.58B | $65.18B | 3.7% | 83.0% | $1.85B | $16.81B |
| FY 2024 | $226.83B | $45.04B | 3.3% | 81.3% | $3.25B | $8.82B |
| FY 2023 | $204.98B | $34.12B | 44.0% | 79.3% | -$6.38B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAH // BETA 0.90
LLY // BETA 0.51